Review



human hnscc cell lines scc25  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    ATCC human hnscc cell lines scc25
    Human Hnscc Cell Lines Scc25, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1362 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/SCC-25/pm42314513-84-0-16
    Average 97 stars, based on 1362 article reviews
    human hnscc cell lines scc25 - by Bioz Stars, 2026-11
    97/100 stars

    Images

    Related Articles

    Cell Culture:

    Article Title: Multi-Center “Replica Study” Challenges the Impact of Electronic Cigarette Aerosols on Cisplatin Resistance in Head and Neck Cancer Cells
    Article Snippet: .. SCC-25 cells (tongue; ATCC: CRL-1628) were cultured in Dulbecco’s modified Eagle’s Medium (DMEM): F-12 (ATCC: 30-2006) supplemented with 10% fetal bovine serum (FBS), 1% Penicillin/Streptomycin, and 400ng/mL hydrocortisone. .. FaDu cells (pharyngeal; ATCC: HTB-43) were cultured in Eagle’s Minimum Essential Medium (EMEM) (ATCC: 30-2003) supplemented with 10% FBS, and 1% Penicillin/Streptomycin.

    Article Title: Effect of electronic cigarette aerosols on cisplatin resistance in head and neck cancer cells: a collaborative replication study.
    Article Snippet: .. SCC-25 cells (tongue; ATCC: CRL-1628) were cultured in Dulbecco’s modified Eagle’s Medium (DMEM): F-12 (ATCC: 30- ..

    Article Title: Upregulated miR-204-5p inhibits oral squamous cell carcinoma progression via inducing autophagy-promoted apoptosis by targeting PIK3CB
    Article Snippet: .. SCC-15 and SCC-25 cells (the American Type Culture Collection, Manassas, United States) were cultured in DEME-F12 medium (Gibco, NY, United States), and Hacat cells (the Cell Bank of the Chinese Academy of Sciences, Shanghai, China) were cultured in the RPMI-1640 medium (Hyclone, UT, United States). .. All the cell lines supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 0.1 mg/mL streptomycin were cultured in 100-mm culture dishes (JET BIOFIL, China) at 37 °C and in the presence of 5% CO2.

    Article Title: CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
    Article Snippet: SK-Mel-2 cells (ATCC, sourced in 2008) were cultured in DMEMF/12 media (Gibco) supplemented with 5% FBS (Gibco). .. SCC-25 cells (ATCC, sourced in 2008) were cultured in DMEM supplemented with 15% FBS (Gibco) 15 mmol/L HEPES (Corning) and 0.5 mmol/L sodium pyruvate (Corning). .. HEK293 cells (Life Technologies GmbH) were cultured in serum-free FreeStyle F17 Expression Medium (Gibco) containing 1% Penicillin/Streptomycin (PAN-Biotech), 2 mmol/L glutamine (PAN-Biotech), and 0.1% Pluronic (Gibco).

    Modification:

    Article Title: Multi-Center “Replica Study” Challenges the Impact of Electronic Cigarette Aerosols on Cisplatin Resistance in Head and Neck Cancer Cells
    Article Snippet: .. SCC-25 cells (tongue; ATCC: CRL-1628) were cultured in Dulbecco’s modified Eagle’s Medium (DMEM): F-12 (ATCC: 30-2006) supplemented with 10% fetal bovine serum (FBS), 1% Penicillin/Streptomycin, and 400ng/mL hydrocortisone. .. FaDu cells (pharyngeal; ATCC: HTB-43) were cultured in Eagle’s Minimum Essential Medium (EMEM) (ATCC: 30-2003) supplemented with 10% FBS, and 1% Penicillin/Streptomycin.

    Article Title: Effect of electronic cigarette aerosols on cisplatin resistance in head and neck cancer cells: a collaborative replication study.
    Article Snippet: .. SCC-25 cells (tongue; ATCC: CRL-1628) were cultured in Dulbecco’s modified Eagle’s Medium (DMEM): F-12 (ATCC: 30- ..

    Article Title: Anti-CD36 antibodies and their use to treat cancer
    Article Snippet: .. TABLE 6 Mean kinetic data for the SPR-measured interaction of antibodies with CD36 fitted with the 1-to-1 model Antibody ka (1/Ms) kd (1/s) KD (M) Commercial anti-CD36 4.18E+05 1.96E−03 4.71E−09 ONA-0-v1 (IgA) 6.32E+05 3.54E−03 5.85E−09 1G04 (IgG1) 1.00E+05 1.59E−04 1.74E−09 TABLE 7 Mean kinetic data for the SPR-measured interaction with CD36 fitted with the 2-state model Antibody ka1 (1/Ms) kd1 (1/s) ka2 (1/s) kd2 (1/s) KD (M) Commercial 8.69E+04 1.80E−03 5.72E−04 3.32E−04 7.61E−09 anti-CD36 ONA-O-v1 1.08E+05 2.30E−03 5.58E−04 3.93E−04 8.72E−09 (IgA) 1G04 1.57E+05 3.24E−03 1.31E−03 1.64E−04 2.78E−09 (IgG1) TABLE 8 Mean kinetic data for the SPR-measured interaction with CD36 fitted with the bivalent model ka1 ka2 ka1 KD1 KD2 Antibody (1/Ms) kd1 (1/s) (1/RUs) kd2 (1/s) (1/Ms) (M) (M) Commercial 2.72E+04 2.06E−03 5.50E−05 3.99E−04 4.13E+02 7.65E−08 9.56E−07 anti-CD36 ONA-0-v1 3.34E+04 2.59E−03 6.74E−05 5.27E−04 5.06E+02 7.73E−08 9.86E−07 (IgA) 1G04 5.23E+04 6.69E−04 6.41E−02 5.48E−02 4.81E+05 1.56E−08 1.14E−07 (IgG1) To measure the ability of anti-CD36 antibodies to alter fatty-acid uptake driven by CD36, commercially available SCC-25 cells (ATCC) were modified by stable transduction with a retroviral vector expressing CD36 and a lentiviral vector expressing luciferase. ..

    Article Title: Functionalized Boron Carbide Nanoparticles as Active Boron Delivery Agents Dedicated to Boron Neutron Capture Therapy
    Article Snippet: .. SCC-25 cells from the human tongue squamous carcinoma line obtained from the American Type Culture Collection (ATCC; CRL-1628) were maintained in a 1:1 mixture of Dulbecco’s modified Eagle’s medium (DMEM; ATCC) and Ham’s F-12 medium (Gibco) containing 100 U/mL penicillin, 100 mg/mL streptomycin, 0.5 mM sodium pyruvate (all from Sigma-Aldrich), 15 mM HEPES (Gibco), 400 ng/mL hydrocortisone (Sigma-Aldrich) and 10% fetal bovine serum (FBS; Sigma-Aldrich). .. PC-3 cells from the human prostate adenocarcinoma line derived from the European Collection of Authenticated Cell Cultures (ECACC; 90112714) were cultured in Ham’s F-12K medium (Gibco) supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin, and 10% FBS (all from Sigma-Aldrich).

    Article Title: Mechanistic Insights into the Anticancer Action of Novel 2‑Hydroxy-1,4-naphthoquinone Thiol Derivatives
    Article Snippet: .. Human SCC-4, SCC-9, and SCC-25 cells, derived from a human oral tongue SCC (squamous cell carcinoma), were obtained from ATCC (CRL-1624, CRL-1629, and CRL-1628, respectively) and maintained in 1:1 DMEM/F12 (Dulbecco’s modified Eagle’s medium and Ham’s F12 medium; Gibco (Thermo Fisher, Waltham, MA, USA)) supplemented with 10% (v/v) FBS (fetal bovine serum; Invitrogen, Thermo Fisher, Waltham, MA, USA) and 400 ng/mL hydrocortisone (Sigma-Aldrich Corporation, St. Louis, MO, USA). .. B16-F10 (melanoma; CRL-6475), HCT-116 (colorectal cancer; CCL-247), and HepG2 (liver cancer; HB-8065), in addition to primary normal human gingival fibroblasts obtained from ATCC (PCS-201-018), were maintained in DMEM supplemented with 10% (v/v) of FBS and were used in a maximum of six passages.

    Derivative Assay:

    Article Title: Coumarin-1,2,3-Triazole Conjugates as Molecular Scaffolds for the Selective Induction of ROS-Driven Apoptosis in Cancer Cells in the Development of Pyruvate Kinase M2 Inhibitors
    Article Snippet: .. Human cancer cell lines SCC-4, SCC-9, and SCC-25 cells, derived from a human oral tongue SCC (squamous cell carcinoma), hepatocellular carcinoma Hep-G2, human colon carcinoma HCT116 cell, and murine tumor-derived cell lines from breast and melanoma (4T1 and B16–F10) were obtained from the American Type Culture Collection (ATCC) (ATCC numbers: CRL-1624, CRL-1629, CRL-1628, HB-8065, CCL-247, CRL-2539, and CRL-6475, respectively). .. Human cancer cell lines SCC-4, SCC-9, and SCC-25 cells, derived from a human oral tongue SCC (squamous cell carcinoma), hepatocellular carcinoma Hep-G2, human colon carcinoma HCT116 cell, and murine tumor-derived cell lines from breast and melanoma (4T1 and B16–F10) were obtained from the American Type Culture Collection (ATCC) (ATCC numbers: CRL-1624, CRL-1629, CRL-1628, HB-8065, CCL-247, CRL-2539, and CRL-6475, respectively).

    Article Title: Mechanistic Insights into the Anticancer Action of Novel 2‑Hydroxy-1,4-naphthoquinone Thiol Derivatives
    Article Snippet: .. Human SCC-4, SCC-9, and SCC-25 cells, derived from a human oral tongue SCC (squamous cell carcinoma), were obtained from ATCC (CRL-1624, CRL-1629, and CRL-1628, respectively) and maintained in 1:1 DMEM/F12 (Dulbecco’s modified Eagle’s medium and Ham’s F12 medium; Gibco (Thermo Fisher, Waltham, MA, USA)) supplemented with 10% (v/v) FBS (fetal bovine serum; Invitrogen, Thermo Fisher, Waltham, MA, USA) and 400 ng/mL hydrocortisone (Sigma-Aldrich Corporation, St. Louis, MO, USA). .. B16-F10 (melanoma; CRL-6475), HCT-116 (colorectal cancer; CCL-247), and HepG2 (liver cancer; HB-8065), in addition to primary normal human gingival fibroblasts obtained from ATCC (PCS-201-018), were maintained in DMEM supplemented with 10% (v/v) of FBS and were used in a maximum of six passages.

    SPR Assay:

    Article Title: Anti-CD36 antibodies and their use to treat cancer
    Article Snippet: .. TABLE 6 Mean kinetic data for the SPR-measured interaction of antibodies with CD36 fitted with the 1-to-1 model Antibody ka (1/Ms) kd (1/s) KD (M) Commercial anti-CD36 4.18E+05 1.96E−03 4.71E−09 ONA-0-v1 (IgA) 6.32E+05 3.54E−03 5.85E−09 1G04 (IgG1) 1.00E+05 1.59E−04 1.74E−09 TABLE 7 Mean kinetic data for the SPR-measured interaction with CD36 fitted with the 2-state model Antibody ka1 (1/Ms) kd1 (1/s) ka2 (1/s) kd2 (1/s) KD (M) Commercial 8.69E+04 1.80E−03 5.72E−04 3.32E−04 7.61E−09 anti-CD36 ONA-O-v1 1.08E+05 2.30E−03 5.58E−04 3.93E−04 8.72E−09 (IgA) 1G04 1.57E+05 3.24E−03 1.31E−03 1.64E−04 2.78E−09 (IgG1) TABLE 8 Mean kinetic data for the SPR-measured interaction with CD36 fitted with the bivalent model ka1 ka2 ka1 KD1 KD2 Antibody (1/Ms) kd1 (1/s) (1/RUs) kd2 (1/s) (1/Ms) (M) (M) Commercial 2.72E+04 2.06E−03 5.50E−05 3.99E−04 4.13E+02 7.65E−08 9.56E−07 anti-CD36 ONA-0-v1 3.34E+04 2.59E−03 6.74E−05 5.27E−04 5.06E+02 7.73E−08 9.86E−07 (IgA) 1G04 5.23E+04 6.69E−04 6.41E−02 5.48E−02 4.81E+05 1.56E−08 1.14E−07 (IgG1) To measure the ability of anti-CD36 antibodies to alter fatty-acid uptake driven by CD36, commercially available SCC-25 cells (ATCC) were modified by stable transduction with a retroviral vector expressing CD36 and a lentiviral vector expressing luciferase. ..

    Transduction:

    Article Title: Anti-CD36 antibodies and their use to treat cancer
    Article Snippet: .. TABLE 6 Mean kinetic data for the SPR-measured interaction of antibodies with CD36 fitted with the 1-to-1 model Antibody ka (1/Ms) kd (1/s) KD (M) Commercial anti-CD36 4.18E+05 1.96E−03 4.71E−09 ONA-0-v1 (IgA) 6.32E+05 3.54E−03 5.85E−09 1G04 (IgG1) 1.00E+05 1.59E−04 1.74E−09 TABLE 7 Mean kinetic data for the SPR-measured interaction with CD36 fitted with the 2-state model Antibody ka1 (1/Ms) kd1 (1/s) ka2 (1/s) kd2 (1/s) KD (M) Commercial 8.69E+04 1.80E−03 5.72E−04 3.32E−04 7.61E−09 anti-CD36 ONA-O-v1 1.08E+05 2.30E−03 5.58E−04 3.93E−04 8.72E−09 (IgA) 1G04 1.57E+05 3.24E−03 1.31E−03 1.64E−04 2.78E−09 (IgG1) TABLE 8 Mean kinetic data for the SPR-measured interaction with CD36 fitted with the bivalent model ka1 ka2 ka1 KD1 KD2 Antibody (1/Ms) kd1 (1/s) (1/RUs) kd2 (1/s) (1/Ms) (M) (M) Commercial 2.72E+04 2.06E−03 5.50E−05 3.99E−04 4.13E+02 7.65E−08 9.56E−07 anti-CD36 ONA-0-v1 3.34E+04 2.59E−03 6.74E−05 5.27E−04 5.06E+02 7.73E−08 9.86E−07 (IgA) 1G04 5.23E+04 6.69E−04 6.41E−02 5.48E−02 4.81E+05 1.56E−08 1.14E−07 (IgG1) To measure the ability of anti-CD36 antibodies to alter fatty-acid uptake driven by CD36, commercially available SCC-25 cells (ATCC) were modified by stable transduction with a retroviral vector expressing CD36 and a lentiviral vector expressing luciferase. ..

    Retroviral:

    Article Title: Anti-CD36 antibodies and their use to treat cancer
    Article Snippet: .. TABLE 6 Mean kinetic data for the SPR-measured interaction of antibodies with CD36 fitted with the 1-to-1 model Antibody ka (1/Ms) kd (1/s) KD (M) Commercial anti-CD36 4.18E+05 1.96E−03 4.71E−09 ONA-0-v1 (IgA) 6.32E+05 3.54E−03 5.85E−09 1G04 (IgG1) 1.00E+05 1.59E−04 1.74E−09 TABLE 7 Mean kinetic data for the SPR-measured interaction with CD36 fitted with the 2-state model Antibody ka1 (1/Ms) kd1 (1/s) ka2 (1/s) kd2 (1/s) KD (M) Commercial 8.69E+04 1.80E−03 5.72E−04 3.32E−04 7.61E−09 anti-CD36 ONA-O-v1 1.08E+05 2.30E−03 5.58E−04 3.93E−04 8.72E−09 (IgA) 1G04 1.57E+05 3.24E−03 1.31E−03 1.64E−04 2.78E−09 (IgG1) TABLE 8 Mean kinetic data for the SPR-measured interaction with CD36 fitted with the bivalent model ka1 ka2 ka1 KD1 KD2 Antibody (1/Ms) kd1 (1/s) (1/RUs) kd2 (1/s) (1/Ms) (M) (M) Commercial 2.72E+04 2.06E−03 5.50E−05 3.99E−04 4.13E+02 7.65E−08 9.56E−07 anti-CD36 ONA-0-v1 3.34E+04 2.59E−03 6.74E−05 5.27E−04 5.06E+02 7.73E−08 9.86E−07 (IgA) 1G04 5.23E+04 6.69E−04 6.41E−02 5.48E−02 4.81E+05 1.56E−08 1.14E−07 (IgG1) To measure the ability of anti-CD36 antibodies to alter fatty-acid uptake driven by CD36, commercially available SCC-25 cells (ATCC) were modified by stable transduction with a retroviral vector expressing CD36 and a lentiviral vector expressing luciferase. ..

    Expressing:

    Article Title: Anti-CD36 antibodies and their use to treat cancer
    Article Snippet: .. TABLE 6 Mean kinetic data for the SPR-measured interaction of antibodies with CD36 fitted with the 1-to-1 model Antibody ka (1/Ms) kd (1/s) KD (M) Commercial anti-CD36 4.18E+05 1.96E−03 4.71E−09 ONA-0-v1 (IgA) 6.32E+05 3.54E−03 5.85E−09 1G04 (IgG1) 1.00E+05 1.59E−04 1.74E−09 TABLE 7 Mean kinetic data for the SPR-measured interaction with CD36 fitted with the 2-state model Antibody ka1 (1/Ms) kd1 (1/s) ka2 (1/s) kd2 (1/s) KD (M) Commercial 8.69E+04 1.80E−03 5.72E−04 3.32E−04 7.61E−09 anti-CD36 ONA-O-v1 1.08E+05 2.30E−03 5.58E−04 3.93E−04 8.72E−09 (IgA) 1G04 1.57E+05 3.24E−03 1.31E−03 1.64E−04 2.78E−09 (IgG1) TABLE 8 Mean kinetic data for the SPR-measured interaction with CD36 fitted with the bivalent model ka1 ka2 ka1 KD1 KD2 Antibody (1/Ms) kd1 (1/s) (1/RUs) kd2 (1/s) (1/Ms) (M) (M) Commercial 2.72E+04 2.06E−03 5.50E−05 3.99E−04 4.13E+02 7.65E−08 9.56E−07 anti-CD36 ONA-0-v1 3.34E+04 2.59E−03 6.74E−05 5.27E−04 5.06E+02 7.73E−08 9.86E−07 (IgA) 1G04 5.23E+04 6.69E−04 6.41E−02 5.48E−02 4.81E+05 1.56E−08 1.14E−07 (IgG1) To measure the ability of anti-CD36 antibodies to alter fatty-acid uptake driven by CD36, commercially available SCC-25 cells (ATCC) were modified by stable transduction with a retroviral vector expressing CD36 and a lentiviral vector expressing luciferase. ..

    Plasmid Preparation:

    Article Title: Anti-CD36 antibodies and their use to treat cancer
    Article Snippet: .. TABLE 6 Mean kinetic data for the SPR-measured interaction of antibodies with CD36 fitted with the 1-to-1 model Antibody ka (1/Ms) kd (1/s) KD (M) Commercial anti-CD36 4.18E+05 1.96E−03 4.71E−09 ONA-0-v1 (IgA) 6.32E+05 3.54E−03 5.85E−09 1G04 (IgG1) 1.00E+05 1.59E−04 1.74E−09 TABLE 7 Mean kinetic data for the SPR-measured interaction with CD36 fitted with the 2-state model Antibody ka1 (1/Ms) kd1 (1/s) ka2 (1/s) kd2 (1/s) KD (M) Commercial 8.69E+04 1.80E−03 5.72E−04 3.32E−04 7.61E−09 anti-CD36 ONA-O-v1 1.08E+05 2.30E−03 5.58E−04 3.93E−04 8.72E−09 (IgA) 1G04 1.57E+05 3.24E−03 1.31E−03 1.64E−04 2.78E−09 (IgG1) TABLE 8 Mean kinetic data for the SPR-measured interaction with CD36 fitted with the bivalent model ka1 ka2 ka1 KD1 KD2 Antibody (1/Ms) kd1 (1/s) (1/RUs) kd2 (1/s) (1/Ms) (M) (M) Commercial 2.72E+04 2.06E−03 5.50E−05 3.99E−04 4.13E+02 7.65E−08 9.56E−07 anti-CD36 ONA-0-v1 3.34E+04 2.59E−03 6.74E−05 5.27E−04 5.06E+02 7.73E−08 9.86E−07 (IgA) 1G04 5.23E+04 6.69E−04 6.41E−02 5.48E−02 4.81E+05 1.56E−08 1.14E−07 (IgG1) To measure the ability of anti-CD36 antibodies to alter fatty-acid uptake driven by CD36, commercially available SCC-25 cells (ATCC) were modified by stable transduction with a retroviral vector expressing CD36 and a lentiviral vector expressing luciferase. ..

    Luciferase:

    Article Title: Anti-CD36 antibodies and their use to treat cancer
    Article Snippet: .. TABLE 6 Mean kinetic data for the SPR-measured interaction of antibodies with CD36 fitted with the 1-to-1 model Antibody ka (1/Ms) kd (1/s) KD (M) Commercial anti-CD36 4.18E+05 1.96E−03 4.71E−09 ONA-0-v1 (IgA) 6.32E+05 3.54E−03 5.85E−09 1G04 (IgG1) 1.00E+05 1.59E−04 1.74E−09 TABLE 7 Mean kinetic data for the SPR-measured interaction with CD36 fitted with the 2-state model Antibody ka1 (1/Ms) kd1 (1/s) ka2 (1/s) kd2 (1/s) KD (M) Commercial 8.69E+04 1.80E−03 5.72E−04 3.32E−04 7.61E−09 anti-CD36 ONA-O-v1 1.08E+05 2.30E−03 5.58E−04 3.93E−04 8.72E−09 (IgA) 1G04 1.57E+05 3.24E−03 1.31E−03 1.64E−04 2.78E−09 (IgG1) TABLE 8 Mean kinetic data for the SPR-measured interaction with CD36 fitted with the bivalent model ka1 ka2 ka1 KD1 KD2 Antibody (1/Ms) kd1 (1/s) (1/RUs) kd2 (1/s) (1/Ms) (M) (M) Commercial 2.72E+04 2.06E−03 5.50E−05 3.99E−04 4.13E+02 7.65E−08 9.56E−07 anti-CD36 ONA-0-v1 3.34E+04 2.59E−03 6.74E−05 5.27E−04 5.06E+02 7.73E−08 9.86E−07 (IgA) 1G04 5.23E+04 6.69E−04 6.41E−02 5.48E−02 4.81E+05 1.56E−08 1.14E−07 (IgG1) To measure the ability of anti-CD36 antibodies to alter fatty-acid uptake driven by CD36, commercially available SCC-25 cells (ATCC) were modified by stable transduction with a retroviral vector expressing CD36 and a lentiviral vector expressing luciferase. ..



    Similar Products

    human hnscc cell lines scc25  (ATCC)
    97
    ATCC human hnscc cell lines scc25
    Human Hnscc Cell Lines Scc25, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/SCC-25/pm42314513-84-0-16
    Average 97 stars, based on 1 article reviews
    human hnscc cell lines scc25 - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier
    scc 25 cells  (ATCC)
    97
    ATCC scc 25 cells
    Scc 25 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/SCC-25/us12643954-1311-162-164
    Average 97 stars, based on 1 article reviews
    scc 25 cells - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier
    scc25 cells  (ATCC)
    97
    ATCC scc25 cells
    Arecoline enhances the migratory and invasive potential of LAMC2 + OSCC cells. (A) Representative immunohistochemical staining images showing LAMC2 expression in OSCC tissues from betel nut chewers and nonchewers. The box‐and‐whisker plot on the right summarizes LAMC2 expression levels; each dot represents an individual clinical specimen (**** p < 0.0001 by Student's t ‐test). (B) Western blot images showing the expression of LAMC2, EMT‐associated markers (N‐cadherin, E‐cadherin, and Vimentin), and GAPDH in OSCC cell lines <t>SCC25</t> and SCC9 under control and arecoline‐treated conditions. (C) Representative Transwell assay images illustrating migratory and invasive capacities of SCC25 and SCC9 cells in control and arecoline‐treated groups. (D) Bar plots showing the quantification of migration and invasion assays for SCC25 and SCC9 cells under control and arecoline‐treated conditions ( n = 3, *** p < 0.001, **** p < 0.0001 by Student's t ‐test).
    Scc25 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/SCC-25/pmc13239442-312-2-8
    Average 97 stars, based on 1 article reviews
    scc25 cells - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier
    cell lines scc 25 atcc cat  (ATCC)
    97
    ATCC cell lines scc 25 atcc cat
    Arecoline enhances the migratory and invasive potential of LAMC2 + OSCC cells. (A) Representative immunohistochemical staining images showing LAMC2 expression in OSCC tissues from betel nut chewers and nonchewers. The box‐and‐whisker plot on the right summarizes LAMC2 expression levels; each dot represents an individual clinical specimen (**** p < 0.0001 by Student's t ‐test). (B) Western blot images showing the expression of LAMC2, EMT‐associated markers (N‐cadherin, E‐cadherin, and Vimentin), and GAPDH in OSCC cell lines <t>SCC25</t> and SCC9 under control and arecoline‐treated conditions. (C) Representative Transwell assay images illustrating migratory and invasive capacities of SCC25 and SCC9 cells in control and arecoline‐treated groups. (D) Bar plots showing the quantification of migration and invasion assays for SCC25 and SCC9 cells under control and arecoline‐treated conditions ( n = 3, *** p < 0.001, **** p < 0.0001 by Student's t ‐test).
    Cell Lines Scc 25 Atcc Cat, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/SCC-25/pm42167233-734-46-49
    Average 97 stars, based on 1 article reviews
    cell lines scc 25 atcc cat - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier
    scc 25 crl 1628 cells  (ATCC)
    97
    ATCC scc 25 crl 1628 cells
    Arecoline enhances the migratory and invasive potential of LAMC2 + OSCC cells. (A) Representative immunohistochemical staining images showing LAMC2 expression in OSCC tissues from betel nut chewers and nonchewers. The box‐and‐whisker plot on the right summarizes LAMC2 expression levels; each dot represents an individual clinical specimen (**** p < 0.0001 by Student's t ‐test). (B) Western blot images showing the expression of LAMC2, EMT‐associated markers (N‐cadherin, E‐cadherin, and Vimentin), and GAPDH in OSCC cell lines <t>SCC25</t> and SCC9 under control and arecoline‐treated conditions. (C) Representative Transwell assay images illustrating migratory and invasive capacities of SCC25 and SCC9 cells in control and arecoline‐treated groups. (D) Bar plots showing the quantification of migration and invasion assays for SCC25 and SCC9 cells under control and arecoline‐treated conditions ( n = 3, *** p < 0.001, **** p < 0.0001 by Student's t ‐test).
    Scc 25 Crl 1628 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/SCC-25/bio_rxiv__64898__2026__04__02__716058-50-3-10
    Average 97 stars, based on 1 article reviews
    scc 25 crl 1628 cells - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier
    scc 25 tongue squamous cell carcinoma  (ATCC)
    97
    ATCC scc 25 tongue squamous cell carcinoma
    Arecoline enhances the migratory and invasive potential of LAMC2 + OSCC cells. (A) Representative immunohistochemical staining images showing LAMC2 expression in OSCC tissues from betel nut chewers and nonchewers. The box‐and‐whisker plot on the right summarizes LAMC2 expression levels; each dot represents an individual clinical specimen (**** p < 0.0001 by Student's t ‐test). (B) Western blot images showing the expression of LAMC2, EMT‐associated markers (N‐cadherin, E‐cadherin, and Vimentin), and GAPDH in OSCC cell lines <t>SCC25</t> and SCC9 under control and arecoline‐treated conditions. (C) Representative Transwell assay images illustrating migratory and invasive capacities of SCC25 and SCC9 cells in control and arecoline‐treated groups. (D) Bar plots showing the quantification of migration and invasion assays for SCC25 and SCC9 cells under control and arecoline‐treated conditions ( n = 3, *** p < 0.001, **** p < 0.0001 by Student's t ‐test).
    Scc 25 Tongue Squamous Cell Carcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/SCC-25/us12589163-1142-16-25
    Average 97 stars, based on 1 article reviews
    scc 25 tongue squamous cell carcinoma - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier
    oscc cell lines scc25  (ATCC)
    97
    ATCC oscc cell lines scc25
    Arecoline enhances the migratory and invasive potential of LAMC2 + OSCC cells. (A) Representative immunohistochemical staining images showing LAMC2 expression in OSCC tissues from betel nut chewers and nonchewers. The box‐and‐whisker plot on the right summarizes LAMC2 expression levels; each dot represents an individual clinical specimen (**** p < 0.0001 by Student's t ‐test). (B) Western blot images showing the expression of LAMC2, EMT‐associated markers (N‐cadherin, E‐cadherin, and Vimentin), and GAPDH in OSCC cell lines <t>SCC25</t> and SCC9 under control and arecoline‐treated conditions. (C) Representative Transwell assay images illustrating migratory and invasive capacities of SCC25 and SCC9 cells in control and arecoline‐treated groups. (D) Bar plots showing the quantification of migration and invasion assays for SCC25 and SCC9 cells under control and arecoline‐treated conditions ( n = 3, *** p < 0.001, **** p < 0.0001 by Student's t ‐test).
    Oscc Cell Lines Scc25, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/SCC-25/pm41896711-56-12-34
    Average 97 stars, based on 1 article reviews
    oscc cell lines scc25 - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    Arecoline enhances the migratory and invasive potential of LAMC2 + OSCC cells. (A) Representative immunohistochemical staining images showing LAMC2 expression in OSCC tissues from betel nut chewers and nonchewers. The box‐and‐whisker plot on the right summarizes LAMC2 expression levels; each dot represents an individual clinical specimen (**** p < 0.0001 by Student's t ‐test). (B) Western blot images showing the expression of LAMC2, EMT‐associated markers (N‐cadherin, E‐cadherin, and Vimentin), and GAPDH in OSCC cell lines SCC25 and SCC9 under control and arecoline‐treated conditions. (C) Representative Transwell assay images illustrating migratory and invasive capacities of SCC25 and SCC9 cells in control and arecoline‐treated groups. (D) Bar plots showing the quantification of migration and invasion assays for SCC25 and SCC9 cells under control and arecoline‐treated conditions ( n = 3, *** p < 0.001, **** p < 0.0001 by Student's t ‐test).

    Journal: MedComm

    Article Title: Comprehensive Integrated Single‐Cell and Spatial Transcriptomics Unveil the Dynamic Landscape of Betel Nut‐Associated Oral Mucosal Carcinogenesis and Its Tumor Microenvironment

    doi: 10.1002/mco2.70796

    Figure Lengend Snippet: Arecoline enhances the migratory and invasive potential of LAMC2 + OSCC cells. (A) Representative immunohistochemical staining images showing LAMC2 expression in OSCC tissues from betel nut chewers and nonchewers. The box‐and‐whisker plot on the right summarizes LAMC2 expression levels; each dot represents an individual clinical specimen (**** p < 0.0001 by Student's t ‐test). (B) Western blot images showing the expression of LAMC2, EMT‐associated markers (N‐cadherin, E‐cadherin, and Vimentin), and GAPDH in OSCC cell lines SCC25 and SCC9 under control and arecoline‐treated conditions. (C) Representative Transwell assay images illustrating migratory and invasive capacities of SCC25 and SCC9 cells in control and arecoline‐treated groups. (D) Bar plots showing the quantification of migration and invasion assays for SCC25 and SCC9 cells under control and arecoline‐treated conditions ( n = 3, *** p < 0.001, **** p < 0.0001 by Student's t ‐test).

    Article Snippet: SCC9 and SCC25 cells were obtained from the American Type Culture Collection.

    Techniques: Immunohistochemical staining, Staining, Expressing, Whisker Assay, Western Blot, Control, Transwell Assay, Migration